Market Access News | pharmaphorum

News

EMA starts twin reviews of AZ, Daiichi’s Dato-DXd

The clock has started ticking in the EU on two marketing applications for AstraZeneca and Daiichi Sankyo’s TROP2-targeting antibody-drug conjugate datopotamab deruxtecan i

News

4SC files maintenance CTCL therapy Kinselby in EU

German biotech 4SC has filed its oral HDAC inhibitor Kinselby with the EMA, hoping to provide a much-needed new therapy for patients with the rare cancer cutaneous T-Cell

News

MHRA okays first drug under new mutual recognition scheme

A new formulation of Amgen’s cancer treatment Xgeva is the first to be approved in the UK under a new procedure designed to speed up access to new therapies.

News

In U-turn, NICE backs first drug for AL amyloidosis

Almost four years after it was approved in Europe to treat the incurable rare disease systemic amyloid light-chain (AL) amyloidosis, Johnson & Johnson’s Darzalex has b

News

Clinigen educates on early access to rare disease therapies

On Rare Disease Day, Clinigen has launched a campaign to try to encourage doctors and patients to explore how they can get early access to investigational therapies.

News

PHTI to review digital hypertension, mental health tools

The Peterson Health Technology Institute (PHTI) has added hypertension and mental health to the list of digital health technologies (DHTs) that it will review for their cl

EMA starts twin reviews of AZ, Daiichi’s Dato-DXd

4SC files maintenance CTCL therapy Kinselby in EU

MHRA okays first drug under new mutual recognition scheme

In U-turn, NICE backs first drug for AL amyloidosis

Clinigen educates on early access to rare disease therapies

PHTI to review digital hypertension, mental health tools

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks